Press Releases News Year None202020192018201720162015201420132012 IVERIC bio Reports Second Quarter 2020 Operational Highlights and Financial Results Aug 05, 2020 | IVERIC bio to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference Aug 04, 2020 | IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Aug 03, 2020 | IVERIC bio to Report Second Quarter 2020 Financial Results and Host Conference Call on Wednesday, August 5, 2020 Jul 29, 2020 | IVERIC bio Announces the Addition of Mark S. Blumenkranz, M.D., M.M.S., to its Board of Directors Jul 16, 2020 | IVERIC bio Announces First Patient Dosed in Second Zimura® Phase 3 Clinical Trial for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration Jun 30, 2020 | IVERIC bio, Inc. Announces Closing of Public Offering and Concurrent Private Placement with $160 Million in Gross Proceeds Jun 22, 2020 | IVERIC bio, Inc. Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Jun 18, 2020 | IVERIC bio, Inc. Announces Proposed Offering of Common Stock and Pre-Funded Warrants and Concurrent Private Placement Jun 17, 2020 | IVERIC bio Announces Positive Zimura 18 Month Data Supporting the 12 Month Efficacy Findings: Continuous Positive Treatment Effect with Favorable Safety Profile in Geographic Atrophy Secondary to Age-Related Macular Degeneration in a Phase 3 Trial Jun 15, 2020 | Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
IVERIC bio to Report Second Quarter 2020 Financial Results and Host Conference Call on Wednesday, August 5, 2020 Jul 29, 2020 |
IVERIC bio Announces the Addition of Mark S. Blumenkranz, M.D., M.M.S., to its Board of Directors Jul 16, 2020 |
IVERIC bio Announces First Patient Dosed in Second Zimura® Phase 3 Clinical Trial for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration Jun 30, 2020 |
IVERIC bio, Inc. Announces Closing of Public Offering and Concurrent Private Placement with $160 Million in Gross Proceeds Jun 22, 2020 |
IVERIC bio, Inc. Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Jun 18, 2020 |
IVERIC bio, Inc. Announces Proposed Offering of Common Stock and Pre-Funded Warrants and Concurrent Private Placement Jun 17, 2020 |
IVERIC bio Announces Positive Zimura 18 Month Data Supporting the 12 Month Efficacy Findings: Continuous Positive Treatment Effect with Favorable Safety Profile in Geographic Atrophy Secondary to Age-Related Macular Degeneration in a Phase 3 Trial Jun 15, 2020 |
Press Releases News Year None202020192018201720162015201420132012 IVERIC bio Reports Second Quarter 2020 Operational Highlights and Financial Results Aug 05, 2020 | IVERIC bio to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference Aug 04, 2020 | IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Aug 03, 2020 | IVERIC bio to Report Second Quarter 2020 Financial Results and Host Conference Call on Wednesday, August 5, 2020 Jul 29, 2020 | IVERIC bio Announces the Addition of Mark S. Blumenkranz, M.D., M.M.S., to its Board of Directors Jul 16, 2020 | IVERIC bio Announces First Patient Dosed in Second Zimura® Phase 3 Clinical Trial for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration Jun 30, 2020 | IVERIC bio, Inc. Announces Closing of Public Offering and Concurrent Private Placement with $160 Million in Gross Proceeds Jun 22, 2020 | IVERIC bio, Inc. Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Jun 18, 2020 | IVERIC bio, Inc. Announces Proposed Offering of Common Stock and Pre-Funded Warrants and Concurrent Private Placement Jun 17, 2020 | IVERIC bio Announces Positive Zimura 18 Month Data Supporting the 12 Month Efficacy Findings: Continuous Positive Treatment Effect with Favorable Safety Profile in Geographic Atrophy Secondary to Age-Related Macular Degeneration in a Phase 3 Trial Jun 15, 2020 | Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
IVERIC bio to Report Second Quarter 2020 Financial Results and Host Conference Call on Wednesday, August 5, 2020 Jul 29, 2020 |
IVERIC bio Announces the Addition of Mark S. Blumenkranz, M.D., M.M.S., to its Board of Directors Jul 16, 2020 |
IVERIC bio Announces First Patient Dosed in Second Zimura® Phase 3 Clinical Trial for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration Jun 30, 2020 |
IVERIC bio, Inc. Announces Closing of Public Offering and Concurrent Private Placement with $160 Million in Gross Proceeds Jun 22, 2020 |
IVERIC bio, Inc. Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Jun 18, 2020 |
IVERIC bio, Inc. Announces Proposed Offering of Common Stock and Pre-Funded Warrants and Concurrent Private Placement Jun 17, 2020 |
IVERIC bio Announces Positive Zimura 18 Month Data Supporting the 12 Month Efficacy Findings: Continuous Positive Treatment Effect with Favorable Safety Profile in Geographic Atrophy Secondary to Age-Related Macular Degeneration in a Phase 3 Trial Jun 15, 2020 |
